Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/highlights-on-chronic-lymphocytic-leukemia-presented-at-the-sWQTmZbo3o
References (17)
-
J. Woyach, A. Ruppert, N. Heerema, Weiqiang Zhao, Allison Booth, W. Ding, N. Bartlett, D. Brander, P. Barr, K. Rogers, S. Parikh, S. Coutre, A. Hurria, G. Lozanski, S. Nattam, R. Larson, H. Erba, M. Litzow, C. Owen, J. Atkins, J. Abramson, R. Little, Scott Smith, R. Stone, S. Mandrekar, J. Byrd (2018)
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202Blood
-
P. Hillmen, A. Rawstron, K. Brock, Samuel Vicente, F. Yates, R. Bishop, D. Macdonald, C. Fegan, A. McCaig, A. Schuh, A. Pettitt, J. Gribben, P. Patten, S. Devereux, A. Bloor, C. Fox, Francesco Forconi, Talha Munir (2018)
Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity StudyBlood
-
(2018)
CombinedIbrutinib andVenetoclaxinPatientswithTreatment - NaïveHigh - Risk Chronic Lymphocytic Leukemia ( CLL ) . Presented at the 2018 ASH Annual Meeting , December 4 , 2018 ; San Diego , CA -
A. Wiener, I. Wexler (1949)
Results of therapy of erythroblastosis with exchange transfusion.Blood, 4 1
-
T. Shanafelt, V. Wang, N. Kay, C. Hanson, S. O'brien, J. Barrientos, H. Erba, R. Stone, M. Litzow, M. Tallman (2018)
A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)Blood
-
A. Mato, J. Svoboda, E. Prak, S. Schuster, P. Tsao, C. Dorsey, P. Becker, D. Brander, S. Nasta, D. Landsburg, C. King, B. Morrigan, K. Kennard, L. Roeker, A. Zelenetz, M. Purdom, D. Paskalis, P. Sportelli, H. Miskin, M. Weiss, M. Shadman (2018)
Phase I/II Study of Umbralisib (TGR-1202) in Combination with Ublituximab (TG-1101) and Pembrolizumab in Patients with Relapsed/Refractory CLL and Richter's TransformationBlood
-
T. Siddiqi, J. Soumerai, W. Wierda, J. Dubovsky, H. Gillenwater, L. Gong, A. Mitchell, J. Thorpe, Lina Yang, K. Dorritie (2018)
Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with IbrutinibBlood
-
R. Greil, G. Fraser, B. Leber, R. Marks, G. Quaresmini, J. Middeke, G. Semenzato, W. Schary, M. Boyer, M. Breuleux, N. Crompton, K. Humphrey, P. Marlton (2018)
Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO StudyBlood
-
N. Jain, M. Keating, P. Thompson, A. Ferrajoli, J. Burger, G. Borthakur, Koichi Takahashi, Z. Estrov, N. Fowler, T. Kadia, M. Konopleva, Y. Alvarado, M. Yilmaz, C. Dinardo, P. Bose, M. Ohanian, N. Pemmaraju, E. Jabbour, K. Sasaki, R. Kanagal-Shamanna, K. Patel, J. Jorgensen, N. Garg, Xuemei Wang, K. Sondermann, Nichole Cruz, Chongjuan Wei, A. Ayala, W. Plunkett, H. Kantarjian, V. Gandhi, W. Wierda (2018)
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)Blood
-
J. Byrd, J. Woyach, R. Furman, P. Martin, S. O'brien, Jennifer Brown, D. Stephens, J. Barrientos, S. Devereux, P. Hillmen, J. Pagel, Dih-Yih Chen, A. Hamdy, R. Izumi, P. Patel, M. Wang, N. Jain, W. Wierda (2018)
Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 StudyClinical Lymphoma Myeloma and Leukemia
-
C. Moreno, R. Greil, F. Demirkan, A. Tedeschi, B. Anz, L. Larratt, M. Šimkovič, O. Samoilova, J. Novak, D. Ben-yehuda, V. Strugov, D. Gill, J. Gribben, E. Hsu, Cathy Zhou, F. Clow, D. James, L. Styles, I. Flinn (2018)
Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATEBlood
-
A. Kater, P. Hillmen, B. Eichhorst, A. Langerak, T. Kipps, C. Owen, M. Boyer, K. Humphrey, E. Punnoose, Jue Wang, B. Chyla, M. Verdugo, J. Wu, Yanwen Jiang, M. Mobasher, J. Seymour (2018)
First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO StudyBlood
-
(2018)
Ibrutinib Plus Vene - toclaxinRelapsed / RefractoryCLL : Resultsof theBloodwise TAPClarity Study . Presentedat the 2018 ASHAnnualMeet - ing , December 4 , 2018 ; SanDiego , CA -
(2018)
Acalabrutinib in Patients withRelapsed/Refractory (R/R)andHigh-Risk, TreatmentNaive (TN) Chronic Lymphocytic Leukemia (CLL) -
(2018)
Ibrutinib Plus VenetoclaxinRelapsed/RefractoryCLL:Resultsof theBloodwise TAPClarity Study -
Clare Sun, Pia Nierman, I. Ahn, Janet Valdez, J. Lotter, S. Soto, S. Herman, T. Covey, A. Hamdy, R. Izumi, Dongmei Liu, P. Patel, A. Wiestner (2018)
Acalabrutinib in Patients with Relapsed/Refractory (R/R) and High-Risk, Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)Blood
-
P. Staber, A. Chanan-Khan, Talha Munir, D. Niederweiser, J. Schetelig, J. Middeke, M. Dirnberger-Hertweck, P. Kelemen, J. Weirather, S. Parikh, S. Stilgenbauer, C. Wendtner, J. Woyach (2018)
Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor TherapyBlood
- Publisher
- Springer Journals
- Copyright
- Copyright © 2019 by Springer-Verlag GmbH Austria, part of Springer Nature
- Subject
- Medicine & Public Health; Oncology; Medicine/Public Health, general
- ISSN
- 1865-5041
- eISSN
- 1865-5076
- DOI
- 10.1007/s12254-019-00521-y
- Publisher site
- See Article on Publisher Site
Abstract
Chronic lymphocytic leukemia (CLL) treatment strategies have improved and changed dramatically in the last few years. Insights presented at the last American Society of Hematology meeting changed standards of care in the first-line treatment. In patients <70 years with unmutated CLL, ibrutinib is the new standard resulting in a survival benefit compared to FCR (fludarabine, cyclophosphamide and rituximab). There was no progression-free survival or overall survival benefit in the subgroup of mutated patients for ibrutinib-based regimens. A randomized trial again showed no benefit of rituximab when added to ibrutinib compared to ibrutinib alone. Moreover, several promising treatment strategies in the relapsed/refractory setting were presented. The combination of ibrutinib with venetoclax reduces tumor lysis syndrome risk and generates MRD (minimal residual disease) negativity.
Journal
memo - Magazine of European Medical Oncology – Springer Journals
Published: Sep 17, 2019